Blood test to predict prostate cancer spread to bones
Part of Cancer, Kidney & urinary clinical trials.
This study examines special particles in your blood called exosomes to see if they can predict whether prostate cancer might spread to your bones. Researchers will collect a blood sample before any cancer treatment to look for RNA signatures that might indicate bone metastasis risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer confirmed by biopsy
- You have not yet started any prostate cancer treatment (hormone therapy, radiation, chemotherapy, or surgery)
- You are willing to have a blood draw (about 2 teaspoons) before any treatment or biopsy
- You have not had another active cancer in the past 2 years (skin cancer doesn't count)
- You are 18 years or older
- You can provide written permission to participate in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a simple blood test to look for microRNA patterns that may help spot prostate cancer earlier and avoid unnecessary biopsies. If you have elevated PSA or suspicious findings, this test might give more information about your risk.
This study collects samples to find biomarkers related to bone metastases in common cancers. It might help doctors better understand why cancer spreads to bones.
This study explores whether a simple blood test that looks at tiny particles called exosomes can help diagnose prostate cancer, possibly reducing the need for biopsies. If you have higher PSA levels and are scheduled for a biopsy, this trial might be a fit.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This study looks at whether a blood test that finds tiny amounts of remaining cancer (called minimal residual disease) can help predict how well treatment works for men with prostate cancer that has spread. If you qualify, you'll help researchers understand if this test can guide future treatment decisions.
This study is checking how well a blood test (liquid biopsy) can find prostate cancer and compare it to a special PET scan (PSMA-PET). If you qualify, you might help improve how we track prostate cancer without needing more invasive biopsies.
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.